July 15, 2020 Warsaw, Poland

Dear Colleagues,

After careful consideration of the spreading coronavirus epidemic, the recent notifications issued by the WHO, the Polish Ministry of Health and the evolving travel restrictions in US (ban of international travels till 31 December 2020), the organizing committee of the Brain Tumors meeting was forced to make a decision to reschedule the meeting to June 21-23, 2021 to ensure safety for our delegates, speakers and sponsors. The safety, health and well-being of all our attendees will always be of extreme importance for us.

Most of the speakers have already confirmed their participation, so the program is not significantly changed

We are looking forward to welcoming you to Warsaw in June 2021! We will prepare and disseminate the new program in the next few days. The administrative details, registration fee, and venue remain the same. 

The online services will remain in place for the new meeting date and the registration for new attendees will be still open.

Best regards
Bozena Kaminska 

On behalf of the Organizing Committee

--

 

April 6, 2020 Warsaw, Poland

Dear All, 

I do hope all of you are safe and healthy. After carefully evaluating the development of the COVID-19 pandemic, we have made the decision to postpone the 5th Brain Tumors Meeting 2020 - From Biology to Therapy till autumn 2020. 

Due to early introduction of self-isolation and social distancing, the current situation in Poland is relatively good, with the number of infected people just over 4000 and low death rate (as of April 6, 2020), but it means that we have likely a slowly growing epidemic and June 2020 would be too early to safely organize the meeting. Also, in general, traveling could be limited and some restrictions may prevent active participation. We hope the situation will slowly come back to normal by the summer when COVID-19 pandemic would be over in most of the countries. To be on a safe side, we decided to move the meeting to October 14-16, 2020. 

The meeting will now take place on the new dates of October 14-16, 2020 at the Nencki Institute in Warsaw, Poland. Most speakers confirmed their participation on new dates, so there will be no major change in the program. A deadline for registration and abstract submission would be extended till August 31, 2020. 

If you are not willing to participate, we will reimburse registration fees already paid. If you are planning to attend, the already paid registrations will be valid.  

Thank you for understanding.

Best regards,
Bozena Kaminska

 --


Dear Colleagues,

We are closely following all news about coronavirus pandemic. As of now, there are no recommendations to cancel or reschedule the Brain Tumors 2020 meeting since it is scheduled for late June and the predicted number of participants is below 300. Currently, Poland is not very affected, but there are some travel restrictions in Italy and other European countries that may affect participation of certain speakers. We will be monitoring the situation and depending on the outcome (potential restrictions or cancelations from speakers or participants), we will make a decision by the end of April whether to proceed or reschedule the meeting to November/December 2020. We have a number of participants registered and some financial arrangements have been made so we would rather reschedule than cancel the meeting. It is estimated that the pandemic will have subdued by April, so we have decided to hold the final decision until then. I can assure you that the local committee will take all efforts to make an optimal decision respecting all concerns and recommendations.

Best regards,
Bozena Kaminska

--


Dear Colleagues,

It is my big pleasure and honor to invite You to participate in the 'Brain Tumors Meeting 2020 - From Biology to Therapy', which will take place on June 22-24, 2020 in Warsaw, Poland. The conference is organized by the Nencki Institute of Experimental Biology and Foundation of Clinical and Experimental Oncology. The conference will take place at the Conference hall of the Neurobiology Center, Nencki Institute of Experimental Biology in Warsaw, Poland.

The main advantage of the conference is its high scientific quality, avoidance of parallel scientific sessions, enough planned time for discussion, specialized topics focused on basic and clinical research on brain tumor biology and therapy. During the Meeting the lectures will be presented by internationally recognized experts and will cover recent advances in pathobiology, immunology, diagnosis and therapy of brain tumors. Complex interactions between tumor cells, microenvironment and host immunity will be discussed. The conference provides unique opportunity for students and young investigators to present posters and be selected for short talks. Collegial environment will foster interdisciplinary cross-talks and spark new scientific collaborations.


 

See You in Warsaw

Prof. Bozena Kaminska

podpis

Chair of the Organizing Committee

Confirmed plenary speakers:
John de Groot, MD Anderson Cancer Center, USA

Confirmed speakers:
Kenneth Aldape, National Cancer Institute, USA
Oren Becher, Northwestern University, USA
Martin van den Bent, Erasmus MC Cancer Institute, Rotterdam, the Netherlands
Etty (Tika) Benveniste, University of Alabama at Birmingham, USA
Agnieszka Bronisz, Harvard Medical School/Mossakowski Medical Institute, Poland
Maria G. Castro, University of Michigan Medical School, USA
Waldemar Debinski, Wake Forest Baptist Health, Comprehensive Cancer Center, USA
Neta Erez, Tel Aviv University, Israel
Dinorah Friedmann-Morvinski, Tel Aviv University, Israel
Constantinos G. Hadjipanayis, Icahn School of Medicine, Mount Sinai, USA
Dolores Hambardzumyan, Icahn School of Medicine, Mount Sinai, USA
Petra Hamerlik, Danish Cancer Society Research Center, Denmark
Dieter Henrik Heiland, University of Freiburg Medical Center, Germany 
Christel Herold-Mende, University of Heidelberg, Germany
Katrin Lamszus, University Medical Center Hamburg-Eppendorf, Germany
Bozena Kaminska, Nencki Institute of Experimental Biology, Poland
Anna Kenney, Winship Cancer Institute, Emory University, USA
Jacek Majewski, McGill University, Canada
Alessandro Michelucci, Luxemburg Institute of Health, Luxemburg
Houtan Noushmehr, Henry Ford Health System, USA
Waldemar Priebe, MD Anderson Cancer Center, USA
Guido Reifenberger, University of Dusseldorf, Germany
Itay Tirosh, Weizmann Institute of Science, Isreal
Maciej Wiznerowicz, International Institute for Molecular Oncology, Poland